Filing Flows › Amneal Pharmaceuticals (AMRX) › Q4 2025
Amneal Pharmaceuticals (AMRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 27, 2026
Amneal Pharmaceuticals (AMRX) reported revenue of $814M for the fourth quarter 2025 (Q4 2025), +11% from a year earlier and +4% from the quarter before. Operating margin was 13.8%, net earnings $35.1M (4.3% of revenue).
Amneal Pharmaceuticals, Q4 2025: revenue $814M (+12% year over year), operating margin 13.8%, net earnings $35.1M, operating cash flow $130M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $814M | +4% | +11% |
| Gross profit | $297M | +8% | +13% |
| Operating profit | $112M | +59% | +48% |
| Net earnings | $35.1M | 15× | — |
| Operating cash flow | $130M | +10% | +10% |
| Free cash flow | $109M | +2% | +5% |
What changed
Revenue was $814.3M in Q4 2025, up 11% year over year and up 4% from the previous quarter.
Gross margin was 36.5%, up 0.5 points from a year earlier. Operating profit was $112.0M, a 13.8% margin (up 3.4 points year over year). Of the extra revenue versus a year earlier, 43% reached operating profit, above the 10% margin then. Operating expenses fell 1% while revenue rose 11%. The fastest-growing cost line was SG&A (+14%). Net earnings were $35.1M. The effective tax rate was 10.3%.
Operating cash flow was $130.3M (up 10% year over year), 263% of net income including minority interests. Non-cash charges added back $8.2M of share-based compensation. Working capital and other items added $72.5M. Capital expenditures of $21.8M left free cash flow of $108.5M.
Questions
What was Amneal Pharmaceuticals' revenue in the fourth quarter 2025?
Amneal Pharmaceuticals (AMRX) reported revenue of $814M for the fourth quarter 2025 (Q4 2025), +11% from a year earlier and +4% from the quarter before.
Was Amneal Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $112M (13.8% of revenue) and net earnings $35.1M.